« Back
Single Practice Six-Year Experience Treating Food Allergy With Oral Immunotherapy
Poster Title: Single Practice Six-Year Experience Treating Food Allergy With Oral Immunotherapy
Submitted on 09 Mar 2015
Author(s): DM Pence1, AR Hague1, RL Wasserman1,2, SK Silvers1,2, RW Sugerman1,2, M Herbert3
Affiliations: 1Dallas Food Allergy Center/DallasAllergyImmunology, 2Medical City Children’s Hospital, 3Dept Clinical Research, Medical City Dallas Hospital
This poster was presented at American Academy of Allergy Asthma and Immunology Annual Meeting 2015
Poster Views: 2,071
View poster »

Poster Information
Abstract: Rationale: Interest in FOIT in the practice setting continues to increase. We report a review of 241 FOIT treated patients who reached their target dose and 53 who did not.

Methods: Retrospective record review of all patients initiating FOIT from 6/10/08 to 6/30/14, approved by the North Texas IRB. Patients received increasing FOIT doses with target doses of (mg of protein) cashew 2000, egg 4545, milk 8000, peanut 2000, pecan 2190, wheat 8000.

Results: 82% of patients reached their target dose. 66% of patients who reached the target dose and 62% of those who did not had a history of systemic reaction to the allergenic food before FOIT treatment.
Median FOIT asIgE (kU/L) dropped at least 48% immediately after FOIT completion. The median decrease in asIgE (kU/L) from before FOIT to one month after reaching the target dose was 48% whole egg, 67% egg white, 72% milk, and 51% peanut. Patients who discontinued treatment had a higher pre-FOIT asIgE than those who reached target.
Patients who discontinued FOIT had more epinephrine treated reactions (ETR) during escalation (2.56 ETR/1000 doses given) than those who reached target (0.86/1000 doses given).

Conclusions: A history of anaphylaxis before starting FOIT does not help predict which patients will reach the target dose. Those with higher pre-FOIT asIgE may be less likely to reach the target dose. An increase in reactions during escalation may be a predictor of patients that are more likely to discontinue FOIT.
Summary: We report a more-than-six-year experience with food oral immunotherapy (FOIT) in a private allergy practice setting. Most patients can be desensitized to one or more allergenic foods. Ongoing evaluation and modification of the FOIT procedures improves outcomes and acceptability. FOIT can be successfully performed in an allergy office.
References: 1. Bock SA, Muñoz-Furlong A, Sampson H. J Allergy Clin Immunol. 2007;119:1016–1018
2. Clark S, Espinola J, Rudders SA, et. al. J Allergy Clin Immunol. 2011;127:682–683
3. Herbert LJ, Dahlquist LM. J Clin Psychol Med Settings. 2008;15:261–269
4. Ostblom E, Egmar AC, Gardulf A, et. al. Allergy. 2008;63:211–218
5. Akeson N, Worth A, Sheikh A. Clin Exp Allergy. 2007;37:1213–1220
6. King RM, Knibb RC, Hourihane JO. Allergy 2009;64:461-8.
7. JA Lieberman, C Weiss, TJ Furlong, et al. Ann Allergy Asthma Immunol. 2010;105:282–286
8. Hague AR, Wasserman RL, Sugerman RW. J Allergy Clin Immunol , 129:2, AB29. AAAAI. Oralando, FL, March 2012.
9. Factor JM, Mendelson L, Lee J, et. al. 2012; Ann Allergy Asthma Immunol. 109:348-352.
10. Wasserman RL, Factor JM, Baker JW, et. al. 2014. J Allergy Clin Immunol Pract. 2:91-96
Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons